Rituximab for the treatment of acute refractory ITP

Sei Gyung Kim, Donna Whyte Stewart, Farzana D. Pashankar

Research output: Contribution to journalArticle

Abstract

Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
Volume36
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Idiopathic Thrombocytopenic Purpura
Rho(D) Immune Globulin
Therapeutics
Intravenous Immunoglobulins
Adrenal Cortex Hormones
Rituximab

Keywords

  • Acute immune thrombocytopenic purpura
  • children
  • rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Rituximab for the treatment of acute refractory ITP. / Kim, Sei Gyung; Whyte Stewart, Donna; Pashankar, Farzana D.

In: Journal of Pediatric Hematology/Oncology, Vol. 36, No. 3, 2014.

Research output: Contribution to journalArticle

@article{77873b5f3f094901aa382fb447fabead,
title = "Rituximab for the treatment of acute refractory ITP",
abstract = "Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.",
keywords = "Acute immune thrombocytopenic purpura, children, rituximab",
author = "Kim, {Sei Gyung} and {Whyte Stewart}, Donna and Pashankar, {Farzana D.}",
year = "2014",
doi = "10.1097/MPH.0b013e318292f006",
language = "English (US)",
volume = "36",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Rituximab for the treatment of acute refractory ITP

AU - Kim, Sei Gyung

AU - Whyte Stewart, Donna

AU - Pashankar, Farzana D.

PY - 2014

Y1 - 2014

N2 - Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.

AB - Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.

KW - Acute immune thrombocytopenic purpura

KW - children

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84897543342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897543342&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e318292f006

DO - 10.1097/MPH.0b013e318292f006

M3 - Article

C2 - 23669737

AN - SCOPUS:84897543342

VL - 36

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -